Hormonal therapy is effective and safe for cryptorchidism caused by idiopathic hypogonadotropic hypogonadism in adult males

Front Endocrinol (Lausanne). 2023 Jan 18:13:1095950. doi: 10.3389/fendo.2022.1095950. eCollection 2022.

Abstract

Background: Hormonal therapy is a reasonable treatment for cryptorchidism caused by idiopathic hypogonadotropic hypogonadism (IHH). However, the clinical evidence on whether it is effective and safe for the treatment of cryptorchidism caused by IHH is lacking.

Aim: To evaluate the effect of hormonal therapy in testicular descent, puberty development, and spermatogenesis in adult males with cryptorchidism caused by IHH.

Methods: This retrospective study included 51 patients with cryptorchidism caused by IHH from the Andrology Clinic of University affiliated teaching hospital. Patients were divided into two groups: group A patients received hormonal therapy; group B patients received surgical treatment for cryptorchidism followed by hormonal therapy.

Results: The rate of successful testicular descent following hormonal therapy (19/32 in group A) or surgical treatment (11/19 in group B) shows no statistically significant difference. There was also no statistically significant difference in penile length, Tanner stage of pubic hair, testicular volume, and success rate of spermatogenesis between the two groups. Testicular atrophy was seen in a single patient in group B.

Conclusions: Hormone therapy in adult males with cryptorchidism caused by IHH is effective and safe regarding testicular descent, puberty development, and spermatogenesis. This study provides new insight into the treatment of cryptorchidism caused by IHH and highlights that hormonal therapy could be an effective, safe, and economic treatment option for cryptorchidism in males caused by IHH.

Keywords: cryptorchidism; hormonal therapy; idiopathic hypogonadotropic hypogonadism; spermatogenesis; testicular descent.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Cryptorchidism* / drug therapy
  • Humans
  • Hypogonadism* / drug therapy
  • Male
  • Retrospective Studies

Supplementary concepts

  • Idiopathic Hypogonadotropic Hypogonadism

Grants and funding

This work was supported by the National Natural Science Foundation of China (No. 81671443 and 81601270).